Xbrane Biopharma AB (publ) has carried out a primary issuance of shares of approximately SEK 170 million at a subscription price of SEK 72 per share. The subscription price was determined through an accelerated book-building procedure. A number of Swedish and international institutional investors, including Systematic Group AB (Ashkan Pouya), Swedbank Robur Fonder, Cicero Fonder, TIN Fonder and Lancelot Asset Management have subscribed for shares in the transaction.
Xbrane Biopharma develops biological drugs based on a platform technology that provides substantially lower production costs compared to competing systems. Xbrane Biopharma has a portfolio of biosimilar candidates that together addresses EUR 53 billion in expected annual peak sales of the respective reference medicines. The leading biosimilar candidate Ximluci® is under registration in Europe with a planned launch in the first quarter of 2023.
Kempen & Co and Pareto Securities acted as Joint Global Coordinators and Joint Bookrunners. Baker McKenzie acted as legal advisor to Xbrane Biopharma with an international capital markets team consisting of Joakim Falkner, Johanna Flink, Olof Larsson, Carl Bohman and Elsa Sefastsson in Stockholm as well as Charles Farnsworth and Adam Farlow in London.